QBL reveals major cannabis product distribution scheme

QBL reveals major cannabis product distribution scheme

The cannabis subsidiary of Queensland Bauxite (ASX: QBL) has secured new distribution deal which could bring a new drug into the mainstream by the end of 2018.

Medical Cannabis Limited (MCL) has developed its Australian distribution strategy for the Canntab XR tablet, a drug developed by Canadian pharmaceuticals company Canntab.

Canntab XR is designed to provide pain relief to cancer patients and provide an alternative to opioid-based treatments.

While the drug is still in clinical trials, MCL expects to start importing Canntab XR during 1H18 and make it available through the government's special access scheme (SAS) soon after.

"While the SAS is currently limited in scale, the company will continue studies for broader market penetration in tandem with the SAS," said the company in a market update.

A cross section of the Canntab XR tablet

Pnina Feldman, chairperson of Queensland Bauxite, said the focus throughout 2018 will be preparing the product for market.

"We believe this product is well positioned compared to competing cannabis products and will make a lasting difference to many Australians in need," said Feldman.

"[This year] is shaping up to be a milestone year and we look forward to seeing the first revenues from our medical division shortly."

While initial revenue from Canntab XR is expected to come through the SAS, following the clinical trial phase, the company will use gathered data to market the drug to a wider segment.

MCL expects Canntab XR will attract strong interest "given the concerns of the medical industry around the safety of smoked and vaporised cannabinoids".

The announcement follows a string of major updates for Queensland Bauxite and MCL since the beginning of 2018.
In January, MCL appointed 'Amazon John' Easterling to its board of directors.

Easterling is a veteran developer of therapeutical products from plants and an experienced cultivator of medical cannabis.
In 2008, Easterling married Olivia Newton-John, another avid supporter of the industry. The duo continues to grow the Olivia Newton-John Cancer Wellness and Research Centre in Melbourne.

Just over a month following Easterling's appointment, MCL signed another landmark agreement with a research team in Israel.

MCL will sponsor the Technion Research and Development Foundation, based in Haifa, as it aims to discern the effects of medical cannabis in multiple sclerosis patients.

Under the agreement, MCL will retain an exclusive licence for any product which is derived from the research.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

The party’s over: Splendour in the Grass festival cancelled for 2024

The party’s over: Splendour in the Grass festival cancelled for 2024

Splendour in the Grass, Australia’s largest winter music fest...